Methylcellulose

Overview

Methyl cellulose polymer consisting of numerous linked glucose molecules used as a stabiliser, thickener and emulsifier for foodstuffs and cosmetics. The Degree of Substitution (DS) of a given form of methyl cellulose is defined as the average number of substituted hydroxyl groups per glucose with a theoretical maximum of 3, however more typical values are 1.3 2.6. Methyl cellulose is a hydrophilic white powder in pure form and dissolves in cold (but not in hot) water, forming a clear viscous solution or gel. It is available under a variety of trade names as a treatment for constipation. Like cellulose, it is not digestible, not toxic, and not allergenic

Indication

Solutions containing methyl cellulose are used as substitute for tears or saliva if the natural production of these fluids is disturbed. It is also used or constipation, diverticulosis, hemorrhoids and irritable bowel syndrome. Used in the manufacture of capsules in nutritional supplements. Its edible and nontoxic properties provide a vegetarian alternative to the use of gelatin.

Associated Conditions

Constipation
Dry Eye Syndrome (DES)

Clinical Trials

Title	Posted	Study ID	Phase	Status	Sponsor
Effects of Topical Insulin on Corneal Epithelium Healing After Corneal Crosslinking in Patients With Keratoconus	2024/09/19	NCT06601101	Phase 3	Recruiting	University of Campinas, Brazil
Artificial Tears to Prevent Nasolacrimal Duct Obstruction in Patients Treated with Radioactive Iodine for Thyroid Cancer	2023/08/21	NCT05999630	Phase 3	Recruiting	Vanderbilt University Medical Center
Midodrine as Novel Treatment of Post-Cardiopulmonary Bypass Vasoplegic Syndrome	2020/12/16	NCT04668859	Phase 4	Terminated	Medstar Health Research Institute
Effect of Topical Besifloxacin on Ocular Surface Bacterial Microbiota Prior to Cataract Surgery	2020/09/09	NCT04542759	Phase 1	Completed	Instituto de Oftalmología Fundación Conde de Valenciana
Parasitic Ulcer Treatment Trial Pilot	2018/03/30	NCT03484507	Phase 2	Active, not recruiting	University of California, San Francisco
Vitamin K to Attenuate Coronary Artery Calcification in Hemodialysis Patients	2012/02/08	NCT01528800	Phase 2	Completed	Dr. Rachel Holden
Management of Irritable Bowel Syndrome in Primary Care (MIBS Trial)	2009/07/08	NCT00934973	Phase 4	Completed	Hazel Everitt
Effect of Anti-inflammatory Topical Prednisolone, Nepafenac and Ketorolac in Intra-operative Mydriasis in Facetectomies	2009/03/19	NCT00865540	Phase 4	UNKNOWN	Clinica Oftamologica Zona Sul
Linezolid Pharmacokinetics (PK) in Multi-Drug Resistant (MDR)/Extensively-Drug Resistant (XDR) Tuberculosis (TB)	2008/06/05	NCT00691392	Phase 1	Completed	Centers for Disease Control and Prevention

FDA Drug Approvals

Approved Product	Manufacturer	NDC Code	Route	Strength	Effective Date
FIBER THERAPY	Preferred Pharmaceuticals Inc.	68788-7995	ORAL	2 g in 19 g	5/12/2025

EMA Drug Approvals

Approved Product	Authorization Holder	Status	Issued Date
No EMA approvals found for this drug.

HSA Drug Approvals

Approved Product	Manufacturer	Approval Number	Dosage Form	Strength	Approval Date
No HSA approvals found for this drug.

NMPA Drug Approvals

Approved Product	Company	Approval Number	Drug Type	Dosage Form	Approval Date
No NMPA approvals found for this drug.

PPB Drug Approvals

Approved Product	Registration No.	Company	Licence No.	Strength	Registration Date
No PPB approvals found for this drug.

TGA Drug Approvals

Approved Product	ARTG ID	Sponsor	Registration Type	Status	Registration Date
No TGA approvals found for this drug.

Health Canada Drug Approvals

Approved Product	Company	DIN	Dosage Form	Strength	Market Date
ENTROCEL SOLUTION 1.8%	tyco healthcare	00750700	Solution - Oral	1.8 %	12/31/1988
PRODIEM BULK FIBRE THERAPY POWDER	novartis consumer health canada inc.	02248225	Powder - Oral	2 G / 19 G	12/3/2003
METHYLAX	seaford pharmaceuticals inc	02248253	Powder - Oral	2 G / 10.2 G	N/A
PRODIEM BULK FIBRE THERAPY POWDER SUGAR FREE	novartis consumer health canada inc.	02248226	Powder - Oral	2 G / 10.2 G	12/3/2003
SLIM-MINT GUM	Stella Pharmaceutical Canada Inc.	00442976	Gum - Oral	44 MG / GUM	12/31/1978
MUROCEL LIQ 1%	bausch & lomb canada inc.	00750808	Drops - Ophthalmic	1 %	12/31/1988
RESTORAFIBRE POWDER SUGAR FREE	Bayer Inc	02461145	Powder - Oral	2 G / 10.2 G	N/A
RESTORAFIBRE CAPLET	Bayer Inc	02461137	Tablet - Oral	500 MG	N/A

CIMA AEMPS Drug Approvals

Approved Product	Company	Registration Number	Pharmaceutical Form	Prescription Type	Status
No CIMA AEMPS (Spain) approvals found for this drug.

Philippines FDA Drug Approvals

Approved Product	Company	License Number	Dosage Form	Strength	Approval Date
No Philippines FDA approvals found for this drug.

Saudi SFDA Drug Approvals

Approved Product	Company	License Number	Dosage Form	Strength	Approval Date
No Saudi SFDA approvals found for this drug.

Malaysia NPRA Drug Approvals

Approved Product	Company	Registration Number	Dosage Form	Strength	Approval Date
No Malaysia NPRA approvals found for this drug.

UK EMC Drug Information

Medicine Name	MA Holder	MA Number	Pharmaceutical Form	Active Ingredient	Authorization Date
No UK EMC drug information found for this drug.

AI-Powered Research

Premium Access